Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020114455 - QUINAZOLINE DIONE SALT COMPOUND CONTAINING PIPERAZINONE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF

Publication Number WO/2020/114455
Publication Date 11.06.2020
International Application No. PCT/CN2019/123295
International Filing Date 05.12.2019
IPC
C07D 403/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 403/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
10linked by a carbon chain containing aromatic rings
Applicants
  • 中国医学科学院药物研究所 INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES [CN]/[CN]
Inventors
  • 徐柏玲 XU, Bailing
  • 陈晓光 CHEN, Xiaoguang
  • 周洁 ZHOU, Jie
  • 季鸣 JI, Ming
  • 李燕 LI, Yan
  • 盛莉 SHENG, Li
Agents
  • 北京尚诚知识产权代理有限公司 SHANGCHENG & PARTNERS
Priority Data
201811481275.605.12.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) QUINAZOLINE DIONE SALT COMPOUND CONTAINING PIPERAZINONE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
(FR) COMPOSÉ DE SEL DE QUINAZOLINE DIONE CONTENANT DE LA PIPÉRAZINONE, PROCÉDÉ DE PRÉPARATION CORRESPONDANT, COMPOSITION PHARMACEUTIQUE ET UTILISATION ASSOCIÉES
(ZH) 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途
Abstract
(EN)
The present invention relates to a quinazoline-2,4-diketone salt compound containing piperazinone as a PARP1/2 inhibitor, a preparation method therefor, a pharmaceutical composition containing the compound, and a combined application of the compound serving as a medicine, especially as an antitumor drug or as a tumor drug sensitizer together with an antitumor drug.
(FR)
La présente invention concerne un composé de sel de quinazoline-2,4-dicétone contenant de la pipérazinone en tant qu'inhibiteur de PARP1/2, un procédé de préparation correspondant, une composition pharmaceutique contenant le composé, et une utilisation combinée du composé servant de médicament, en particulier en tant que médicament antitumoral ou en tant que sensibilisateur de médicament antitumoral conjointement avec un médicament antitumoral.
(ZH)
本发明涉及含有哌嗪酮的喹唑啉-2,4-二酮盐类化合物作为PARP1/2抑制剂及其制备方法,含有所述化合物的药物组合物,以及所述化合物作为药物,尤其是作为抗肿瘤药物或作为肿瘤药物增敏剂与抗肿瘤药物联合应用。
Also published as
Latest bibliographic data on file with the International Bureau